Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study

Background/purpose Preclinical vascular inflammation models have demonstrated effective suppression of arterial wall lesional T cells through inhibition of Janus kinase 3 and JAK1. However, JAK inhibition in patients with giant cell arteritis (GCA) has not been prospectively investigated. Methods We performed a prospective, open-label, pilot study of baricitinib (4 mg/day) with a tiered glucocorticoid (GC) entry and accelerated taper in patients with relapsing GCA. Results 15 patients were enrolled (11, 73% female) with a mean age at entry of 72.4 (SD 7.2) years, median duration of GCA of 9 (IQR 7–21) months and median of 1 (1–2) prior relapse. Four (27%) patients entered the study on prednisone 30 mg/day, 6 (40%) at 20 mg/day and 5 (33%) at 10 mg/day. Fourteen patients completed 52 weeks of baricitinib. At week 52, 14/15 (93%) patients had ≥1 adverse event (AE) with the most frequent events, including infection not requiring antibiotics (n=8), infection requiring antibiotics (n=5), nausea (n=6), leg swelling (n=2), fatigue (n=2) and diarrhoea (n=1). One subject required baricitinib discontinuation due to AE. One serious adverse event was recorded. Only 1 of 14 (7%) patients relapsed during the study. The remaining 13 patients achieved steroid discontinuation and remained in disease remission during the 52-week study duration. Conclusion In this proof-of-concept study, baricitinib at 4 mg/day was well tolerated and discontinuation of GC was allowed in most patients with relapsing GCA. Larger randomised clinical trials are needed to determine the utility of JAK inhibition in GCA. Trial registration number NCT03026504.

[1]  E. Matteson,et al.  Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. , 2016, Rheumatology.

[2]  C. Turesson,et al.  2018 Update of the EULAR recommendations for the management of large vessel vasculitis , 2019, Annals of the rheumatic diseases.

[3]  S. Reichenbach,et al.  Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. , 2019, Rheumatology.

[4]  S. Gabriel,et al.  Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. , 2003, Arthritis and rheumatism.

[5]  J. Kremer,et al.  Baricitinib in Patients with Refractory Rheumatoid Arthritis. , 2016, The New England journal of medicine.

[6]  J. Stone,et al.  Trial of Tocilizumab in Giant‐Cell Arteritis , 2017, The New England journal of medicine.

[7]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[8]  L. Mouthon,et al.  Efficacy of baricitinib for refractory large vessel vasculitis. , 2021, Rheumatology.

[9]  D. Misra,et al.  A systematic review of clinical and preclinical evidences for Janus kinase inhibitors in large vessel vasculitis , 2021, Clinical Rheumatology.

[10]  P. Merkel,et al.  The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis , 2016, The Journal of Rheumatology.

[11]  J. Jover,et al.  Combined Treatment of Giant-Cell Arteritis with Methotrexate and Prednisone , 2001, Annals of Internal Medicine.

[12]  Yoshiya Tanaka,et al.  Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis: A 52-week, randomized, single-blind, extension study , 2018, Modern rheumatology.

[13]  M. González-Gay,et al.  Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. , 2019, Seminars in arthritis and rheumatism.

[14]  J. Krischer,et al.  A Randomized, Double‐Blind Trial of Abatacept (CTLA‐4Ig) for the Treatment of Giant Cell Arteritis , 2017, Arthritis & rheumatology.

[15]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[16]  M. Sonnenblick,et al.  Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. , 1994, The Journal of rheumatology.

[17]  S. Reichenbach,et al.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[18]  C. Zerbini,et al.  Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate , 2020, Arthritis care & research.

[19]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[20]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis & rheumatology.

[21]  M. Genovese,et al.  Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis , 2018, The Journal of Rheumatology.

[22]  L. Tian,et al.  Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis , 2017, Circulation.

[23]  Mahboob Rahman,et al.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.

[24]  M. Alba,et al.  Relapses in Patients With Giant Cell Arteritis , 2014, Medicine.

[25]  A. Aouba,et al.  JAK Inhibitor Effectiveness in Giant-Cell Arteritis With Large-Vessel Involvement Assessed by 18F-FDG PET-CT. , 2021, Clinical nuclear medicine.

[26]  Li Wang,et al.  Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study , 2021, Annals of the Rheumatic Diseases.

[27]  M. Genovese,et al.  Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate , 2014, Annals of the rheumatic diseases.

[28]  G. Hunder.  The early history of giant cell arteritis and polymyalgia rheumatica: first descriptions to 1970. , 2006, Mayo Clinic proceedings.

[29]  P. Merkel,et al.  Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. , 2007, Arthritis and rheumatism.

[30]  D. M. van der Heijde,et al.  Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment , 2017, Arthritis & rheumatology.

[31]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[32]  J. Paolini,et al.  OP0059 MAVRILIMUMAB (ANTI GM-CSF RECEPTOR Α MONOCLONAL ANTIBODY) REDUCES RISK OF FLARE AND INCREASES SUSTAINED REMISSION IN A PHASE 2 TRIAL OF PATIENTS WITH GIANT CELL ARTERITIS , 2021 .

[33]  J. Stone,et al.  Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial , 2021 .

[34]  M. Weinblatt,et al.  Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[35]  P. Merkel,et al.  Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study , 2015, The Journal of Rheumatology.

[36]  I. McInnes,et al.  JAK inhibitors and infections risk: focus on herpes zoster , 2020, Therapeutic advances in musculoskeletal disease.

[37]  C-R Wang,et al.  Extended-release tofacitinib improves refractory Takayasu’s arteritis , 2021, Scandinavian journal of rheumatology.

[38]  E. Mola,et al.  A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects , 2007, Annals of the rheumatic diseases.

[39]  K. Migita,et al.  A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib. , 2019, Rheumatology.

[40]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis , 2021, Arthritis care & research.

[41]  G. Baron,et al.  Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial , 2013, Annals of the rheumatic diseases.

[42]  T. Horita,et al.  Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis , 2020, Annals of the Rheumatic Diseases.

[43]  S. Hayat.  Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial , 2008 .

[44]  Mengtao Li,et al.  Tofacitinib in patients with refractory Takayasu’s arteritis , 2020, Rheumatology.

[45]  T. Therneau,et al.  The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. , 2011, Arthritis and rheumatism.

[46]  A. Enjuanes,et al.  Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis , 2015, Annals of the rheumatic diseases.

[47]  H. Spiera,et al.  Methotrexate in giant-cell arteritis. , 2001, Annals of internal medicine.

[48]  K. Kalunian,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. , 2002, Arthritis and rheumatism.

[49]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.